UBS AG’s preliminary terms set a public issue price of $1,000.00 per note for trigger callable contingent Yield notes linked to the least performing underlying. Investors face exposure to the linked assets, UBS AG’s creditworthiness and market pricing, while the notes are not bank deposits or FDIC-insured securities.
Key Highlights
- UBS AG’s notes are scheduled to mature on or about September 7, 2028.
- Underwriting compensation can reach $7.25 per note, while UBS AG’s proceeds are at least $992.75 per note.
- The preliminary public issue price is $1,000 per note for trigger callable contingent yield notes tied to the least performing linked asset.
UBS AG’s preliminary terms put the public issue price at $1,000 per note for trigger callable contingent yield notes tied to the least performing linked asset. The securities are due on or about September 7, 2028, subject to completion of the final offering documents. The preliminary structure shows Underwriting compensation of up to $7.25 per note.
Conflicts and Secondary-Market Conditions
UBS AG will receive the net proceeds from the initial public offering, excluding underwriting compensation, creating another conflict under the same rule.
FAQs
Q: What is the UBS AG notes issue price?
A: The preliminary public issue price is $1,000 per note. The securities are trigger callable contingent yield notes linked to the least performing referenced asset.
Q: When are the UBS AG notes due?
A: The notes are scheduled to mature on or about September 7, 2028. Their final terms depend on completion and delivery of the offering documents in final form.
Q: When are the securities due?
A: The securities are due on or about September 7, 2028. Their stated timing remains subject to completion of the final offering documents.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.